Vertex to acquire Crinetics Pharmaceuticals for $10 billion

July 6, 2026 4:04 PM

Vertex Pharmaceuticals (NASDAQ: VRTX) has agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85.00 per share in cash, representing a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found